Yüksel Ürün
@DrYukselUrun
Medical Oncologist, Prof.Dr. @AnkaraUni - Genitourinary Cancers Expert - Believer in #Science #Diversity #Equity #Advocacy
Dear Colleague, We invite you to join the Prostate Cancer Care Disparity Analysis Project (ProGAP) — [NCT06612034] — by completing our brief 6–8 minute survey exploring global disparities in prostate cancer treatment. Your voice is essential to shaping more equitable care…
Dear Colleague, Join the Prostate Cancer Care Disparity Analysis Project (ProGAP) (NCT06612034) by taking our quick 6–8 minute survey on global disparities in prostate cancer treatment. Your input is vital in shaping better care. Thank you! Link👇👇👇 qualtricsxmvcbtqb5rf.qualtrics.com/jfe/form/SV_7a……
Her gün 7000 adım atarsan: ⭐️ Ölüm riski %47 ❤️ Kalp hastalığı riski %25 🌟 Kanserden ölüm riski %37 💖 Tip 2 diyabet riski %14 🧠 Demans riski %38 😔 Depresyon belirtileri %22 ⭐️ Düşme riski %28 AZALIYOR Yani her adım, hayata atılmış bir adım. Bugün biraz yürü, kendin için.…
Obesity isn't just weight, it's a disease linked to fat distribution and major health risks. 🧠 Stroke 💓 Heart disease 🎯 Diabetes 🧬 13+ cancers BMI helps estimate risk, but doesn’t tell the full story. #Obesity #Cancer #PublicHealth #prevention @theNCI @OncoAlert
Updated results from KEYNOTE-B61: First-line pembrolizumab + lenvatinib in advanced non-clear-cell RCC shows: ✅ ORR 51% ✅ CR in 8.2% ✅ Median DOR 19.5 mo A promising option for nccRCC. #oncology #kidneycancer @EUplatinum @AlbigesL @OncoAlert @Uromigos pubmed.ncbi.nlm.nih.gov/40707309/
Could not think of a better person to take on this tremendous role for this @AmericanCancer journal! Congrats @DrRanaMcKay! @DrChoueiri @BradMcG04 @shilpaonc @VivekSubbiah @neerajaiims @PGrivasMDPhD
Please join us in welcoming @DrRanaMcKay as our new Section Editor for Genitourinary Disease! Dr. McKay is a medical oncologist who specializes in treating people with urogenital cancers. Her research interests include precision medicine and biomarker development. @OncoAlert
📚 Kanserin kitabı bu kadar kalın olmak zorunda mıydı? Eğer sigara içilmese, obezite olmasa, enfeksiyonlar (HPV, HBV, H. pylori…) önlenebilseydi… Bir kısmı kader değil, tercih. Bir kısmı genetik değil, politika. Bir kısmı tedavi değil, önlem gerektirir. #kanser…
Biggest RWD: Cabo/nivo 1st line #kidneycancer 🔴 N=333, 17 countries & 53 centers @aron_project 🟠 mFU 15.9m, mOS not reached, mPFS 33.7m 🟢 ORR 58%, CR 6% 🟣 Poor prognosis: ECOG, sarcomatoid, brain & bone mets 🔵 ≥ G3 AE 37% (Hypertension & HFS) frontiersin.org/journals/oncol…
JAMA Patient Page: What Is Prostate Cancer? @JAMA_current @OncoAlert @PCFnews @APCCC_Lugano #prostatecancer jamanetwork.com/journals/jama/…
Sağlığımızın sorumluluğunu almak, yapabileceğimiz en önemli şeylerden biri. Düzenli hareket etmek, sigaradan uzak durmak ve sağlıklı beslenmek; hem hastalıklardan korur hem de bazılarını geriletebilir. Küçük adımlar, büyük fark yaratır.
The Expanding Role of ADCs in Breast Cancer: Insights After ASCO 2025 ASCO 2025 Sonrası Meme Kanserinde Antikor-İlaç Konjugatlarının (ADC) Rolü @MedikalAkademi medikalakademi.com.tr/oncolife/ @DrYukselUrun @JavierCortesMD
🗣️ “When cure is possible, but toxicity is probable… what matters most?” Let’s talk adjuvant IO in early ccRCC 👇 @OncoAlert @gbanna74 @ravikanesvaran @PGrivasMDPhD @neerajaiims @AlbigesL @montypal @drenriquegrande @DrYukselUrun #IUCS25 #KidneyCancer #GUonc #Immunotherapy
🔵 IUCS25 Clinical Case Poll @OncoAlert @gbanna74 @ravikanesvaran 👨⚕️ 67 y/o man, PS0 🧬 Grade 3 pT3a ccRCC 🚫 No sarcomatoid/rhabdoid features 🧠 Concerned about IO toxicity ❓What drives your adjuvant IO decision?
🚨A must-read review in @NatRevClinOncol ➡️EMT and cancer: what clinicians should know 🎯Cancer cell plasticity fuels metastasis & treatment resistance. @OncoAlert @DrYukselUrun #cancer #Oncology #MedX 👉doi.org/10.1038/s41571…
Everyone asked if ivermectin cures cancer. Sorry, science says NO. But for malaria? Yes, ivermectin cut malaria by 26% in kids. Right drug, right disease. #EvidenceMatters #malaria #NEJM @NEJM DOI: 10.1056/NEJMoa2411262
Great to see the international collaborations moving the field forward and answering questions within randomised trials to further improve clinical outcome & QOL gains for our patients globally. @KariTikkinen @DrYukselUrun @JimCatto @drenriquegrande @ASCO @sheffielduni @cdanicas
Thank you so much @DrYukselUrun @AnkaraUni for the kind words and warm welcome! Great to exchange ideas and explore future collaborations! Looking forward to what we can achieve together. @Uroweb @helsinkiuni @ProfSyedHussain @JimCatto
Congrats to rising star @coskunyazgann and every colleague on this great study tackling a real clinical question for patients with mCRPC. Curiosity, teamwork, and care move science forward. Proud of our team’s work! #Oncology #ProstateCancer @OncJournal @APCCC_Lugano @OncoAlert…
🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior…
🚨 New study alert! 🧪 In our multicenter study of mCRPC patients, we evaluated the impact of enzalutamide vs. abiraterone acetate in the immediately preceding line before ¹⁷⁷Lu-PSMA-617 therapy. 📊 Striking difference in overall survival: ✨ 12.8 months with prior…
☄️ Discover the #IUCS25 programme! Learn about the latest in urological cancer therapies from top international speakers and join expert-led discussions. Attend free online or in-person! Learn more and register now! ⤵️ bit.ly/46TvUao @urologysummit
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care! @AlessiaCim @mishabeltran @AdamSharpMedOnc @EUplatinum @Uroweb @Albert0Briganti @APCCC_Lugano @OncoAlert #ProstateCancer doi.org/10.1016/j.euru…
